Several clinical trials have demonstrated that 4-aminobromide. 4-AP had no consistent effect in restoring conduction to demyelinated axons, even to axons which pyridine (4-AP), a potassium channel-blocking agent, improves symptoms in some patients with multiple were held just on the verge of conducting by adjusting the lesion temperature. However, 4-AP had prominent sclerosis. The beneficial effects have typically been attributed to the restoration of conduction to demyelinated effects that did not involve demyelinated axons, including the potentiation of synaptic transmission and an increase axons, since this effect was previously demonstrated experimentally. However, the clinical dose is~250-1000 in skeletal muscle twitch tension. We propose that these latter effects may be largely responsible for the beneficial times lower than that used experimentally, potentially making extrapolation of the experimental findings action of 4-AP in multiple sclerosis patients. If so, the dominant effects of 4-AP in multiple sclerosis patients are unreliable. To examine the action(s) of 4-AP in demyelinating disorders, the drug was administered at independent of demyelination, and it follows that 4-AP may be beneficial in other neurological disorders in which clinical doses, both in vivo and in vitro, to rat dorsal column axons which had been experimentally function is diminished. demyelinated by the intraspinal injection of ethidium
Introduction
In 1978, Bostock and colleagues demonstrated that conducdiscouraging findings in an initial small trial examining multiple sclerosis patients with pronounced and longtion could be restored to some demyelinated peripheral axons by prolonging the action potential through the use of scorpion standing symptoms , clearly positive results were obtained in patients with milder disease venom (Bostock et al., 1978) . This group later showed that a similar effect could be achieved by applying the potassium of shorter duration (Jones et al., 1983; Stefoski et al., 1987) . A number of subsequent trials have confirmed that channel-blocking agent 4-aminopyridine (4-AP) directly to experimentally demyelinated axons in exposed rat dorsal administration of 4-AP, or the related compound 3,4-diaminopyridine, frequently leads to rapid improvements in a range roots (Sherratt et al., 1980; Bostock et al., 1981) , and this finding was later extended to the rat sciatic nerve (Targ and of symptoms in multiple sclerosis patients (Davis et al., 1990; van Diemen et al., 1992; Bever et al., 1994; Polman Kocsis, 1985 , 1986 ). 4-AP was already in clinical use for the therapy of Lambert-Eaton syndrome (Lundh et al., et al., 1994a, b) , and that these improvements can last for several hours (Davis et al., 1990) following each administra-1977), myasthenia gravis (Lundh et al., 1979) and botulinum poisoning (Ball et al., 1979) , and the experimental demonstration of the drug. Symptomatic improvements have also been reported following 4-AP treatment of patients with spinal tion that 4-AP could restore conduction to demyelinated axons spawned a number of clinical trials in patients with cord injury (Hansebout et al., 1993; Hayes et al., , 1994 . In view of the experimental data, the improvements multiple sclerosis (Jones et al., 1983; Stefoski et al., 1987; van Diemen et al., 1992; Bever et al., 1994) or spinal cord following aminopyridine treatment in both multiple sclerosis and spinal cord injury have often been attributed to the injury (Hansebout et al., 1993; . After restoration of conduction to demyelinated axons (e.g. Jones prepared for terminal electrophysiological examination using et al., 1983; Blight and Gruner, 1987; Stefoski et al., 1987;  methods previously described in detail (Felts and Smith, Davis et al., 1990; van Diemen et al., 1993; Bever, 1994) . 1992). The animals were intubated and mechanically However, there were important differences between the ventilated to maintain end-tidal CO 2 at 4-5%, and the tail early experimental data and the protocols adopted in the vein was cannulated for the administration of pharmacological clinical trials. First, the clinical trials examined 4-AP in agents. A laminectomy was performed from vertebral level multiple sclerosis, a central demyelinating disease, whereas T8 to level L6, the animals were placed in a frame, and a the early experimental data were obtained in peripheral mineral oil recording pool was formed. Unless otherwise demyelinated axons. Perhaps more importantly, there were stated, the pool was maintained at 35°C using radiant heat. marked differences in the concentrations of 4-AP employed.
The dura was opened longitudinally and a pair of platinum In the clinical trials, the prominent proconvulsant activity of wire stimulating electrodes attached to an isolated stimulator 4-AP limited the recommended maximum serum concentra-(DS2, Digitimer Ltd, Welwyn Garden City, UK) was tion to only~1 µM (Bever et al., 1994) , which is~1000-positioned on the dorsal columns. The cathode was placed 5000 times lower than the concentrations of the drug that~5 mm rostral to the rostral margin of the lesion, which was Sherratt and colleagues found effective when applied directly apparent as a translucent region within the dorsal columns. to exposed spinal roots (Sherratt et al., 1980) . In view of
The L2-5 dorsal roots were cut just proximal to their ganglia these differences, we have examined whether clinical doses and placed individually over pairs of platinum wire hook of 4-AP are effective in restoring conduction to central electrodes attached to the headstages of differential a.c. demyelinated axons. In addition, we have examined a number amplifiers (Neurolog System, Digitimer Ltd). The roots of other known effects of 4-AP by which the drug may act were crushed between the recording electrodes to render to improve symptoms, including the potentiation of synaptic monophasic the antidromically conducted compound action transmission, and also the increase of muscle tension. A brief potentials (CAPs). Recordings were filtered to a bandwidth description of some of the data has been presented previously of 8 Hz to 10 kHz. Except where noted, gallamine triethiodide (Felts and Smith, 1994) .
(Flaxedil; Davis and Geck, St Louis, Mo., USA; 10 mg, repeated as necessary to eliminate stimulus-induced muscle contraction) was administered intravenously. The experi-
Methods
mental arrangement is illustrated in Fig. 2E .
Induction of the demyelinating lesion
Two electrophysiological methods were used to detect the Anaesthesia was induced and maintained in 21 adult rats presence of demyelinated axons, namely prolongation of (Sprague-Dawley and Wistar, male, mean weight 417 g), the refractory period of transmission (RPT) (McDonald and either with halothane (1.5-2%, the balance being O 2 ) or Sears, 1970) and the restoration of conduction upon cooling. with pentobarbital (65 mg/kg intraperitoneally following
The RPTs of the conducting fibres were determined by premedication with 40 µg intraperitoneal atropine), and a recording the response to the second of two stimuli, above quarter (non-irradiated lesions) or complete (irradiated supramaximal voltage, delivered at various interstimulus lesions) laminectomy was performed at the T12 vertebral intervals (Smith, 1980; Smith and Hall, 1980) . The response to level using sterile techniques. The vertebral column was the first stimulus was removed from the records by subtraction held rigidly in a clamp and ethidium bromide (EBr; 1 µl of during the averaging process. The response to cooling of the a 0.5 mg/ml solution in saline) was injected into the left lesion was determined by serial recording while mineral oil dorsal column via a drawn glass micropipette inserted through or saline, either at room temperature (22-24°C) or mildly a small hole in the dura. In some animals the lesion site was chilled, was slowly superfused onto the lesion, taking care immediately irradiated using a 90 Sr/ 90 Yt source (40 Gy of to minimize cooling of either the recording or the stimulatprimarily beta irradiation through a 3 ϫ 5 mm opening in ing sites. a lead-coated shield) (Felts and Smith, 1996) to delay If the RPTs and the response to cooling indicated that remyelination. The wound was closed in layers. Animals were examined daily for postoperative complications; demyelinated axons were present and conducting through the however, none were observed. The experiments were lesion, then the response of the axons to 4-AP administration performed in accordance with the UK Animals (Scientific was determined. Recordings were made of the CAP obtained Procedures) Act, 1986. at the dorsal roots in response to 1 Hz supramaximal stimulation of the dorsal columns rostral to the lesion, both before and at various times after the intravenous injection of Electrophysiological examinations pH 7.4 Felts and Smith, 1992) , allowing the same Naïve animals (n ϭ 12) were used in all these experiments. population of demyelinated axons to be examined serially General anaesthesia was induced and maintained with over several weeks in relatively intact preparations. During halothane (0.8-1.5% in oxygen). Rectal and subcutaneous recording sessions the animals were anaesthetized with halo-(proximal region of the left hindlimb) temperatures were thane and the ends of subcutaneous leads attached to the monitored and maintained between 34.5°and 35.5°C chronically implanted electrodes were exposed through small throughout each experiment. The left tarsus and metatarsus skin incisions. The experimental arrangement is illustrated were immobilized against a rigid metal bar using in Fig. 3C . Animals were intubated and mechanically ventilcyanoacrylate adhesive, and the fourth digit of the left ated to maintain an end-tidal CO 2 concentration of 4-5%. A hindlimb was attached to an isometric force transducer catheter was then introduced into a lateral tail-vein and (Harvard Apparatus, Holliston, Mass., USA). The gallamine (10 mg, repeated as necessary) was infused. Core experimental arrangement is illustrated in Fig. 5B . Recordings temperature was monitored rectally and maintained at 35°C of twitch tension were then made at intervals of 3 or 5 min using a heating blanket, except when body temperature was in response to supramaximal stimulation of the sciatic nerve. allowed to fall in order to determine the effect of cooling on
The stimulating electrodes were either needles inserted conduction. Recordings were fundamentally similar to those percutaneously or platinum wires placed directly on the in the acute preparations, with CAPs and RPTs recorded exposed sciatic nerve distal to the sciatic notch. This latter before, during and after intravenous 4-AP administration.
arrangement was adopted in experiments in which the sciatic nerve was cut at the start of the experiment in order to avoid any contamination of the data with centrally mediated reflex experiments were averaged responses to eight stimuli. In in a brain slice recording chamber to investigate whether experiments in which the sciatic nerve was not severed higher concentrations of 4-AP (i.e. concentrations above proximally at the beginning of recording, it was severed those achievable in vivo) were capable of restoring conduction proximally at the end of the experiment to discern any to central demyelinated axons. Animals (n ϭ 10) were contribution to the contraction from central reflex activity. reanaesthetized with halothane 28-35 days after induction of a demyelinating lesion, and the spinal cord was exposed from~T8 to L2. Two additional normal animals were also (E) Electrophysiological examination of the examined. Following exsanguination under anaesthesia, a effects of 4-AP on synaptic transmission 3.5 cm length of dorsal column containing the lesion was promptly removed, placed in a brain slice recording chamber (Medical Systems Corporation, Greenvale, New York, USA) (i) Study of the H reflex. Anaesthesia, temperature maintenance and hindlimb immobilization were performed modified as shown in Fig. 4 , and superfused with artificial CSF (containing, in mM: NaCl, 123; KCl, 3; CaCl 2 , 1.5; in five rats, as described in section D above. An 'active' recording electrode was inserted into the fourth dorsal NaH 2 PO 4 , 1.2; MgCl 2 , 1; HEPES, 10; glucose, 10; pH 7.4, bubbled with O 2 ). The central and outside lanes were interosseus muscle of the left hind foot, and a 'passive' recording electrode was placed subcutaneously in the same effectively isolated from each other so that the temperature and composition of the fluid in the central lane (which hind foot. These recording electrodes were attached to the headstage of a differential AC amplifier. The experimental contained the lesion) could be altered while leaving conditions at the stimulating and recording sites relatively constant.
arrangement is illustrated in Fig. 6B . Recordings of CMAPs were made in response to submaximal stimulation of the CAPs conducted through the lesion were recorded in response to supramaximal stimulation, and the distribution of the RPTs sciatic nerve via percutaneous needle electrodes at the sciatic notch at 0.1 Hz. Records were taken in groups of five every in 0.1 M cacodylate buffer, pH 7.4) and processed and examined as above. 10 min. After a control recording period (typically 30 min), aliquots of 4-AP were injected intravenously while serial recordings were made.
Results
(ii) Study of the dorsal root reflex. Naïve animals Morphology of the demyelinating lesions (n ϭ 15) were anaesthetized and prepared for terminal Sixteen to 35 days after injection, the EBr lesions were well electrophysiological examination as described in section A circumscribed, lenticular in shape and measured 3-5 mm in above. Stimulating electrodes were placed on the surface of rostrocaudal extent. The lesions were typically unilateral in the dorsal columns in a position analogous to that described distribution ( Fig. 1 ) and, at their widest extent, they occupied in section A above. Recordings were made of the CAP~5 0-80% of the transverse area of the ipsilateral dorsal obtained at the dorsal roots in response to 1 Hz supramaximal column. The lesions contained large numbers of demyelinated stimulation both before and at various times after the axons, and these were exposed directly to the extracellular intravenous administration of aliquots of 4-AP. In some fluid, embedded in vesicular myelin debris, or totally or experiments (n ϭ 5) the directly conducted component of partly ensheathed by Schwann cells, oligodendrocytes or the CAP was separated from the 'dorsal root reflex ' (DRR) astrocytes. Some axons showed signs of early remyelination (i.e. the antidromic reflex activity elicited in dorsal roots via by Schwann cells or, less frequently, by oligodendrocytes. dorsal horn synapses in response to a synchronized volley in More detailed descriptions of the morphology of the EBr primary afferent axons) by the addition of a conditioning lesion have been published previously (Blakemore, 1982 ; stimulus preceding the test stimulus by 20 ms. The DRR is Smith, 1992, 1996) . rendered refractory for Ͼ20 ms by the conditioning stimulus, thus eliminating the DRR from the CAP produced in response to the second, test stimulus. All records obtained were averaged responses to eight stimuli, and were digitized and demyelinated axons: acute preparations in vivo were examined before and after the intravenous administration The time course of the electrophysiological changes of 4-AP. This allowed the effects of 4-AP on conduction and occurring in the EBr lesion in the rat dorsal columns has on synaptic activity to be compared in the same preparation.
been reported previously (Felts and Smith, 1992) . In As described in section E, recordings made using a single agreement with the earlier findings, in all animals with supramaximal stimulus included both the directly conducted demyelinating lesions the CAPs recorded from the lesioned and synaptic components. However, in alternate records the side were much reduced in amplitude ( Fig. 2A) , had a DRR was eliminated by rendering it refractory through the prolonged latency and duration, and revealed that many use of a conditioning stimulus which preceded the test of the axons had prolonged RPTs when compared with stimulus by 20 ms. the contralateral, unlesioned side ( Fig. 2B) . Also, cooling of the part of the dorsal columns containing the lesion had little effect on the form of the recordings made from roots on the non-lesioned side, but the cooling resulted in
Morphological investigation
After in vivo electrophysiological investigations, animals a substantial increase in the area of the monophasic CAP recorded from dorsal roots ipsilateral to the lesion, with demyelinating lesions were perfused via the left ventricle with glutaraldehyde (4% in either 0.15 M cacodylate or particularly in the components conducting with longer latencies (Fig. 2C ). Such increases in conduction through phosphate buffer, pH 7.4) under deep anaesthesia. The spinal cord containing the lesion was removed and processed into demyelinating lesions have been demonstrated previously in the peripheral nervous system, and have been attributed resin, and sections were stained and examined in the light and electron microscope as previously described (Felts and to the restoration of conduction in demyelinated axons (Davis and Jacobson, 1971; Rasminsky, 1973; Bostock Smith, 1992) . Tissues used for in vitro electrophysiological examination were fixed by immersion in glutaraldehyde (4% et al., 1978) . (Fig. 2D ). This dose is well above that used animals, it was clear that the demyelinating lesion resulted as a bolus in clinical trials.
initially in a marked reduction in amplitude of the CAP, A potential complication of some of the experiments which was then partly restored through the appearance of conducted in vivo was the use of neuromuscular blocking peaks with long latency, which then progressively shortened agents, when needed, to eliminate reflex movement of the in latency until they merged with the early peak (if anaesthetized preparation during the spinal stimulation. We present). From our earlier studies (Smith et al., 1979 ; adopted the use of gallamine triethiodide, an agent which, Felts and Smith, 1992) it was known that the appearance like 4-AP (and in common with some other neuromuscular of the later peaks marked the onset of conduction in blocking agents), has potassium channel-blocking activity demyelinated, or very thinly remyelinated, axons, and it (Smith and Schauf, 1981) . This fact potentially raises was during the weeks that these peaks were present that concern when examining the role of 4-AP, but two lines the examination of 4-AP was performed. It was also only of evidence indicate that gallamine neither directly improves during these weeks that temperature was found to have a conduction in demyelinated axons nor alters the response marked effect on the amplitude of the CAP conducted of demyelinated axons to the application of 4-AP. First, through the lesion. Thus, recordings made either before we have recorded CAPs from dorsal roots in response to the lesion was induced, within the few days immediately spinal stimulation in many (n ϾϾ 100) normal and after its induction or in long-term preparations in which lesioned animals, both before and after the intravenous remyelination was complete, showed little effect of cooling administration of gallamine (10 mg). In no preparation has on the form of the CAP. However, during the period of an effect of gallamine on conduction been observed. prominent demyelination (2-6 weeks after injection) a Secondly, in vivo preparations examined either in the reduction of body temperature from 37°C to 33°C resulted presence or absence of gallamine exhibited a similar lack in an increase in the CAP on the ipsilateral side to the of response following injection of 4-AP. Indeed, the animal lesion (Fig. 3A) , just as occurred in the acute preparations: used for illustration in Fig. 2 was not given gallamine the newly conducting axons had the long latency and RPT until the very end of the experiment. We have also (not shown) expected of demyelinated axons. Although examined the effects of 4-AP on demyelinated axons in the absence of gallamine, in vitro (see section C below).
these tests established the presence within the lesion of pathway by the injection of EBr into the left dorsal column at the the dorsal columns rostral to a demyelinating lesion. Recordings T12/13 intervertebral space 28 days previously. The effect of were made in vivo (see section A of Methods) 16 days after the body cooling on the CAP recorded from the right and left sciatic injection of EBr with subsequent irradiation (the lesion from nerves is shown. (A) CAPs recorded at the noted rectal which these recordings were made is illustrated in Fig. 1 ).
temperatures before, during and after cooling of the rat. Note the (A) Antidromically conducted CAPs are shown at equal gains, increase (indicated by the horizontal arrowhead) in a late peak on demonstrating the substantial conduction block present on the the lesioned side when the body temperature was allowed to fall lesioned side. (B) RPT distribution of the axons is illustrated by to 33°C, demonstrating the presence of axons to which showing the response to the second of two stimuli with the given conduction could be restored by cooling. However, the form of interstimulus intervals. The response to the first stimulus has been the CAP showed no evidence (B) of increased conduction at any subtracted during the averaging process (Smith, 1980) (Fig. 3B) . precise temperature control, and under these conditions the effect of varying the temperature on the number of conducting axons was particularly clear (Fig. 4) . Our recording apparatus many axons to which conduction could be restored by was modified to permit the temperature of the middle segment cooling, in the same preparations, on eight different recording occasions, there was no obvious effect on the of the dorsal column to be varied while maintaining a constant temperature at the recording and stimulating sites, and under while the effects on conduction of exposure to artificial CSF containing different concentrations of 4-AP was determined. these conditions temperature had little effect on conduction in normal tissue (Fig. 4A, left panel) . However, temperature
The results of typical experiments are illustrated in Fig. 4B . The lesioned preparation is the same as that illustrated in changes had prominent effects on the form of the CAP conducted through demyelinating lesions in four of the Fig. 4A , and the lesion was cooled to 32°C so that there would be many nerve fibres just above their blocking temperpreparations, and noticeable effects in two preparations (Fig. 4A, right panel) . Such CAPs typically contained two ature, and so just on the verge of conducting. Each group of data represents several superimposed, averaged records, components, an early peak, which conducted with a latency similar to the peak recorded from normal tissue (presumably where one of the records was obtained prior to the administration of 4-AP at a particular concentration and the reflecting conduction in axons spared by the lesion, largely those axons on the contralateral side), and a later peak. While other records were obtained at intervals of~5 min thereafter (for details see legend to Fig. 4) . Records from the dorsal the early peak consisted of axons conducting with normal RPT, the later peak was composed of axons with prolonged column of a naïve animal reveal an absence of effect of 4-AP on normal central axons at concentrations of 25, 100 RPT, indicating that the axons were affected by the demyelinating lesion. The amplitude of the early peak varied little and 500 µM (Fig. 4B, left panel) . All these concentrations are in the supraclinical range; subclinical and clinical doses as the temperature of the lesion was altered, but the amplitude of the later peak varied inversely with temperature, such that were not examined in vitro since these doses had been found to have no effect on conduction in vivo. The middle and it was almost eliminated at body temperature (37°C). Thus, at any temperature chosen within the range examined, there right panels of Fig. 4B reveal that 4-AP at 25 µM had no detectable effect on conduction in the axons contributing to were a number of axons just on the verge of conducting. A temperature was chosen at which slight cooling produced a either of the peaks. When the 4-AP concentration was increased to 500 µM (Fig. 4B , right panel), the amplitude of prominent increase in the amplitude of the second peak, and the temperature was then maintained at this 'blocking' level the early peak again remained unaffected but, in contrast, Fig. 4 Records obtained in vitro from excised dorsal columns from a naïve animal (Control) and an animal in which an experimental demyelinating lesion had been induced 21 days previously (Lesioned). (A) Superimposed averaged records obtained at 1°C intervals as the temperature of the central recording lane (containing the lesion, where present) was raised from 25°to 37°C. The temperature changes had little effect on conduction along the normal central axons, but caused prominent changes in the lesioned tissue. When cooled, the CAP from the lesioned tissue was composed of two peaks. The early peak occurred with a latency similar to that of the control tissue, while the second was delayed, and represented axons with a prolonged RPT (data not shown), indicating that the axons were affected by the demyelinating lesion. The axons constituting the second peak were markedly temperature-sensitive, such that very few were able to conduct at normal body temperature (reproduced with permission from Smith, 1994) . ( administration of higher concentrations of 4-AP (100, 500 or 5000 µM). In no instance, at any concentration of 4-AP, was the short-latency, 'normal' peak seen to increase, nor before the intravenous administration of 4-AP, but the peak was the long-latency, 'demyelinated' peak seen to decrease. tension was always increased in a dose-dependent relationship No significant effect of 25, 100 or 500 µM 4-AP was upon the injection of 4-AP, with a mean threshold dose of observed in normal control tissue.
0.51 mg/kg. In experiments in which the sciatic nerve was cut proximal to the site of stimulation at the start of the experiment (n ϭ 4), the contribution to the records from the (D) Electrophysiological examination of the F wave or H reflex was abolished, but the twitch tension was still increased by 4-AP in a dose-related manner (from
effects of 4-AP on muscle twitch tension
Electrical stimulation of the sciatic nerve with single a threshold dose of 0.44 mg/kg in the illustrated preparation) (Fig. 5A) . In experiments in which the sciatic nerve was supramaximal stimuli caused a twitch contraction of the digital flexor muscles, and thereby of the digits. The curve of severed at the end of the experiment, it was possible to discern two effects of the 4-AP. First, the drug increased the twitch tension developed by the middle toe was reproducible amplitude of the main contraction (due to the M response), directly conducted action potentials, while the prolonged refractoriness of the second peak indicated that it represented but it also caused a magnification of a delayed contraction which was superimposed on the main contraction. The reflex the DRR (this prolonged refractoriness was used to advantage to allow the elimination of the DRR from some recordings; origin of this delayed contraction was confirmed by observing it disappear upon severing the sciatic nerve proximally. see F below). Following 4-AP administration (from 0.43 mg/ kg), the peak representing the DRR was nearly always (14 of 15 experiments) substantially exaggerated in amplitude, and this increase was dependent upon the dose of 4-AP (data (E) Electrophysiological examination of the not shown).
effects of 4-AP on synaptic transmission (i) Study of the H reflex. CMAPs recorded from foot (F) Comparison of the effects of 4-AP on
muscles in response to submaximal stimulation of the sciatic nerve at 0.1 Hz were composed of a small M response and,
conduction through a central demyelinated lesion
in some rats, a larger H reflex (Fig. 6) . Administration of 4-and on central synaptic transmission AP had no effect on the directly conducted M response, but In rats in which a demyelinating lesion had been induced in the amplitude of the H reflex was always greatly increased the dorsal column 28-35 days previously, it was possible to (or appeared and then increased) following 4-AP infusion compare directly the effects of 4-AP on conduction along (Fig. 6A ). This effect was initiated at a dose of 0.35 mg/kg, demyelinated axons with its effect on synaptic transmission, and was dose-related.
as measured by the DRR. Figure 7B shows the distribution of RPTs of axons conducting through a central demyelinating
(ii) Study of the dorsal root reflex. In naïve rats, supramaximal stimulation of the dorsal columns resulted in CAPs recorded from dorsal roots which consisted of a large short-latency peak and a much smaller longer-latency peak. lesion induced by EBr 33 days previously. The records were (Stefoski et al., 1987; Davis et al., 1990; van Diemen et al., 1992; Bever et al., 1994; Polman et al., 1994a) . Several made from the L5 dorsal root ipsilateral to the lesion following supramaximal stimulation of the dorsal column explanations for this apparent discrepancy can be considered. First is the possibility of species differences. While these rostral to the lesion. Nearly all of the conducting axons appeared to be affected by the lesion, as judged by their cannot be ruled out, there is evidence that rats and humans have similar sensitivity to 4-AP. The drug is a potent prolonged latency and prolonged RPT, properties suggestive of conduction in demyelinated or early remyelinated axons.
proconvulsive agent (Spyker et al., 1980; Murray and Newsom-Davis, 1981) and this property limits the maximum Cooling the lesion from 35.5°C with mineral oil or saline at room temperature resulted in a noticeable increase in the dose which can be safely administered systemically. In this study a dose of 1.9-2.0 mg/kg caused mild limb tremors in later components of the CAP (Fig. 7A) , indicating the presence in the conduction pathway of a number of axons lightly anaesthetized animals, and these became pronounced at doses of 2.2-2.7 mg/kg (the maximum doses examined which were just on the verge of conducting at 35.5°C, and to which conduction could be restored by cooling. Despite in vivo in this study). In the absence of anaesthesia it is reasonable to believe that the tremors may have manifested the presence of such axons, the intravenous administration of 4-AP in clinical and supraclinical doses was without themselves as convulsions, and it is notable that a similar convulsant threshold has been reported in humans (Ball effect on the form of the CAP at 35.5°C, when a conditioning stimulus was used to eliminate the DRR (Fig. 7C) . et al., 1979) . A second explanation for the apparent conflict is the Examination of the CAPs without such a conditioning stimulus (Fig. 7D) revealed that, although 4-AP had no effect possibility that the dose used in the rats was not equivalent to that employed in the clinical studies. Direct comparison on the number of axons conducting through the lesion (as represented by the initial peak), it caused a prominent increase of the available experimental and clinical data is hampered by the different ways of reporting the doses administered in the synaptically mediated DRR at both clinical and supraclinical doses. These findings were repeated in each of and by the different routes of administration. In the present experimental study the drug was administered intravenously the four rats examined in this way.
across the dose range used clinically, and the maximum dose (2.7 mg/kg) clearly exceeded the maximum clinical dose.
Clinical trials employing intravenous administration of 4-AP

Discussion
Examination of the effects of 4-AP on conduction along include those of Stefoski and colleagues, who administered doses of 1-5 mg every 10-60 min, to a total dose of central demyelinated axons revealed that 4-AP had no clear effects on the success of conduction through the lesion when 7-35 mg (Stefoski et al., 1987) . Patient weights were not reported, but at a typical weight of 60 kg the highest administered at the low concentrations used clinically. Such concentrations were, however, effective in potentiating synintravenous doses were~0.5 mg/kg. This maximum dose is similar to that used in the study of van Diemen and aptic transmission and increasing muscle twitch tension, and these effects may be important in mediating the beneficial colleagues, who administered 1 mg of 4-AP every 20 min for 1 h, then up to 2.5 mg every 20 min until a maximum effects of 4-AP in demyelinating diseases such as multiple sclerosis. In common with their effects in peripheral demydose of 0.5 mg/kg had been administered or side-effects intervened (van Diemen et al., 1993) . Studies employing elinated axons (Sherratt et al., 1980; Bostock et al., 1981) , higher, supraclinical concentrations (500 µM) of 4-AP were oral administration include those by Jones and colleagues, who administered doses of between 10 and 60 mg of 4-AP effective in reversing conduction block in some central demyelinated axons. (Jones et al., 1983) , and Davis and colleagues, who administered a single oral dose of 10-25 mg (Davis et al., Even though no clear effects of clinically relevant concentrations of 4-AP were observed on the success of 1990). Patient weights were again not reported, but at a typical weight of 60 kg the highest oral doses were conduction along central demyelinated axons, there were many demyelinated axons present within the lesion to which~0.5-1 mg/kg, similar to the oral dose employed by van Diemen and colleagues (0.5 mg /kg) (van Diemen et al., 1992) . conduction could be restored by cooling. This temperature sensitivity of conduction in demyelinated axons is well Thus, the concentrations used in the in vivo parts of the current study were typically slightly above those used clinically. documented experimentally (Rasminsky, 1973; Bostock et al., 1981; Smith, 1994) , and in patients it underlies the expression A third explanation is that the 4-AP failed to gain access to the experimentally demyelinated axons. Such a failure is of Uhthoff's sign (Namerow, 1968; Jonas, 1989) . The restoration of conduction by cooling establishes the presence most unlikely since, at the times examined, the EBr lesion lacks an effective vascular barrier (Felts and Smith, 1996) . within the lesion of axons which are just on the verge of conducting at normal temperature, and such axons should Furthermore, 4-AP has been shown to be permeable to the intact blood-brain barrier (Lemeignan et al., 1984) . form an easy target for drugs such as 4-AP. The failure of 4-AP to restore conduction to such axons at clinical Another potential explanation is that the effects of 4-AP on conduction are delayed, and that the experiments were of concentrations is therefore surprising in view of the clearly beneficial effects of the drug in patients with multiple sclerosis too short a duration for the effects to be observed. 4-AP is known to affect K ϩ channels in neuroblastoma cells at a for the conduction block. Furthermore, it is theoretically likely that at regions of inflammation, which are widespread lower concentration when applied inside rather than outside the cell (Hirsh and Quandt, 1993) , and Davis and colleagues in multiple sclerosis, there may be a reduction in synaptic function. Such a reduction may be expected due to raised have suggested that 4-AP requires time to accumulate inside the axon before it becomes effective in blocking the K ϩ levels of nitric oxide, and perhaps other inflammatory mediators, which interfere with synaptic function (Pineda channels, restoring conduction (Davis et al., 1995) . However, Bostock and colleagues found that direct exposure Yun et al., 1996) ; there is evidence for increased nitric oxide production in multiple sclerosis patients (Bo spinal roots to 4-AP for only 1 min was sufficient for responses to stabilize patients et al., 1994; Johnson et al., 1995; Giovannoni et al., 1997) .
If some symptoms are due to depressed synaptic activity, as show improvements in symptoms within only 25 min after intravenous delivery of 4-AP (Stefoski et al., 1987) . Our we consider likely, then drugs such as 4-AP would be expected to improve these symptoms. For the above reasons, recordings routinely lasted for a longer period following 4-AP injection (e.g . Fig. 2D) ; thus, this explanation seems the effect of 4-AP on synaptic transmission may underlie a major part of the improvements seen in patients with multiple unlikely to account for the lack of observed effect.
It is also possible that, in patients, the clinical deficit may sclerosis.
The experiments conducted in vitro permitted the effects arise not so much from conduction block but from the failure of the axons to conduct repetitively. We have not examined of supraclinical doses to be examined, including doses which would be lethal in vivo. These data demonstrated that 25 µM the effects of 4-AP on this ability, but it was examined in a previous study employing central axons demyelinated by 4-AP typically had no noticeable effect on the success of conduction through a demyelinating lesion, although higher anti-galactocerebroside antibodies (Kaji and Sumner, 1988) . These authors found that even at lethal (in unanaesthetized concentrations (e.g. 500 µM) were increasingly likely to restore conduction to axons affected by the lesion. Higher animals) doses, 4-AP had no effect on the rate-dependent conduction block.
concentrations, in agreement with previous findings (Shi and Blight, 1997) , also showed some evidence of toxicity since Finally, it is possible that the axons in the experimental lesion were unlike those in multiple sclerosis lesions. Howthey became likely to impair conduction in axons conducting with short latency. Four micromolar 4-AP is the threshold ever, although the mechanism of demyelination is different in the two cases, the affected axons have many similarities for increasing the spontaneous activity recorded in the dorsal roots of isolated spinal cord (Al-Zamil et al., 1988) , and in their appearance. Furthermore, there are also no known differences in the electrophysiological properties of the human spontaneous seizure-like discharges in brain slice preparations are produced by 3-10 µM 4-AP (Galvan et al., 1982) . and experimentally demyelinated axons. It seems likely that the response of the experimentally demyelinated axons to Similarly, transmitter release at both excitatory and inhibitory synapses on CA1 neurons in perfused hippocampal slices is 4-AP will be similar to that of axons demyelinated by multiple sclerosis.
enhanced by 10 µM 4-AP (Buckle and Haas, 1982) . Thus the lowest concentration tested in vitro in this study (25 µM) If the experimental data are representative of the human lesion, then it appears that the dominant mechanisms by is already above the threshold at which 4-AP is known to affect synaptic transmission. Supraconvulsant doses of 4-AP which 4-AP improves symptoms in patients may not include the restoration of conduction to blocked axons, as is generally have been reported to restore conduction to central axons demyelinated by anti-galactocerebroside antibodies (Kaji and believed (Jones et al., 1983; Stefoski et al., 1987; Davis et al., 1990; van Diemen et al., 1993; Bever, 1994) . However, Sumner, 1988) . The concentration of 4-AP encountered by axons in the present findings illustrate two effects of 4-AP which are manifest at clinical concentrations and which may be expected multiple sclerosis patients is unknown, and, as has been suggested by others (Davis et al., 1995; Shi and Blight, to lead to clinical improvement. The first arises from the well documented effect of 4-AP in potentiating synaptic 1997), may be affected by the microenvironment in and around the axon. However, experimental observations have transmission, an effect observed both within the central nervous system (Jankowska et al., 1977 (Jankowska et al., , 1982 and at the been made of 4-AP concentrations using whole brain, and CSF. Following an intravenous bolus of 1 mg/kg 4-AP, neuromuscular junction (Lundh, 1978; Molgo et al., 1980) . These effects arise through several mechanisms, including the peak concentration within homogenized rat brain was observed after 30 min and equalled~3 µM (S. J. Roffey, an increase in neurotransmitter release (Jankowska et al., 1982) and an increase in the number of synaptic terminals R. Webster and S. G. Jezequel, unpublished observations presented at the meeting New Concepts of a Blood-Brain activated by an action potential (Obaid et al., 1996 ; see also van Emst et al., 1996) . The present findings confirm that the Barrier, London, July 1994). Although not directly comparable with brain concentration, broadly similar findings central effects are apparent at clinically relevant doses, as evidenced by the potentiation of both the H reflex and the have been reported for 4-AP levels within the CSF. Using a dose higher than that normally encountered clinically, DRR. In a pathway where conduction has been blocked in some, but not all, axons, the augmentation of the synaptic 3.5 mg/kg (approximately one-half of the LD 50 ), Lemeignan and colleagues found that the CSF concentration of 4-AP in efficacy of the remaining active axons may tend to compensate rats 5 min after a single intravenous injection was~5 µM, It is worth noting that some of the effects of 4-AP may be mediated via effects on the immune system. Potassium falling to 2 µM over the next 10 min (Lemeignan et al., 1984) . In dogs, Pratt and colleagues found that a dose channels are increased in T cells by mitogenic stimulation (Matteson and Deutsch, 1984) , and potassium blockade has more similar to that used clinically (0.5 mg/kg) produced a maximum CSF 4-AP concentration of~0.6 µM 6 min been shown to affect T cell mitogenesis (DeCoursey et al., 1984) and activation (Chandy et al., 1984; Rader et al., after intravenous injection (Pratt et al., 1995) . The CSF concentration then fell over the next 7 h to~0.05 µM. In 1996). Notably, potassium channel blockers also inhibit immune responses in vivo (Koo et al., 1997) , and high these two studies (Lemeignan et al., 1984; Pratt et al., 1995) , serum concentration was found typically to be 5-10 times doses have been found to inhibit the adoptive transfer of experimental autoimmune encephalomyelitis by T cells higher than the concentration within the CSF. Serum levels in multiple sclerosis patients have been examined, and (Judge et al., 1997) . However, the prompt onset of at least some of the beneficial effects of 4-AP therapy in patients sustained levels of~100 ng/ml appear to be the maximum that can be tolerated safely (Bever et al., 1994) , a concentrasupports a role for direct effects on the nervous system, such as those reported above. tion equal to 1.06 µM. From these data, plus an extensive examination of data collated from Ͼ40 published studies, If the dominant action of 4-AP in multiple sclerosis is not to restore function to blocked axons, it follows that the use we estimate that even relatively high clinical doses of 4-AP (e.g. 1 mg/kg) are unlikely to produce CSF concentrations of the drug need not be restricted to patients with prominent temperature-sensitive symptoms, as it has sometimes been in Ͼ1-3 µM except, perhaps, for a brief period just after bolus intravenous injection. These 4-AP concentrations are the past (Stefoski et al., 1987; Bever et al., 1994) . Indeed, the positive results in these patients reinforced the view that noticeably lower than those demonstrated in this study to be effective in restoring conduction to demyelinated central 4-AP acted by restoring conduction to demyelinated axons, although the beneficial effects of the drug were sometimes axons.
However, one study has demonstrated electrophysiological evident on symptoms where no temperature sensitivity had been noted by the patients (F. A. Davis, personal communicaeffects of 4-AP on spinal white matter at concentrations within the 1-3 µM clinical range. Shi and Blight examined tion). A later study found that some patients benefited from the administration of 4-AP, even though they lacked the changes in conduction in vitro through crush lesions in the spinal cords of guinea-pigs. They found that the amplitude expression of temperature-sensitive symptoms (van Diemen et al., 1992) . of the CAP was increased by 4-AP with a threshold of 0.5-1 µM and a maximal effect between 10 and 100 µM Although the extent to which 4-AP increases the number of conducting, demyelinated central axons in multiple sclerosis (Shi and Blight, 1997) . This observation indicates that 4-AP can restore conduction to axons damaged by the trauma. The patients remains uncertain, some potentially relevant observations have been made in peripheral axons. Two groups recordings were made 1 month or more after the spinal crush lesion, at a time when histological examination of the spinal have examined the effect of a related potassium channelblocking agent (3,4-diaminopyridine; 3,4-DAP) on cord demonstrated that the lesions contained a mixture of normal axons, partly remyelinated axons, widened paranodes conduction in various demyelinating disorders of the peripheral nervous system. 3,4-DAP was not effective in and infrequent demyelinated axons. This heterogeneous morphology prevents the correlation of electrophysiological restoring conduction in patients with disorders including Guillain-Barré syndrome and chronic inflammatory observations with particular axonal pathologies, but the data suggest that 4-AP may be of value in the therapy of spinal demyelinating polyneuropathy (Bergin et al., 1993; Russell et al., 1995) . These findings may not be directly applicable cord injury.
The second way in which 4-AP may act clinically is by to the effects of 4-AP in the central nervous system, but, in conjunction with the results of the current study, they do increasing the tension developed by muscles (Agoston et al., 1982; Savage, 1985) ; the present findings show that clinical suggest caution in interpreting the beneficial effects of 4-AP in multiple sclerosis as arising from the restoration of doses of 4-AP act to increase skeletal muscle twitch tension. Weakness is a common finding in multiple sclerosis, and it conduction to demyelinated axons. We therefore suggest that the beneficial effects of 4-AP in multiple sclerosis may arise is clear that this effect of 4-AP will tend to reverse this symptom.
primarily from effects which do not involve the demyelinated portions of axons, and our evidence highlights a potential In summary, although we do not discount the possibility that 4-AP may sometimes restore conduction to demyelinated role for the modulation of synaptic transmission. If this is true, it follows that 4-AP may be beneficial in some nonaxons in multiple sclerosis, it seems likely that the dominant effect of the drug will be via other mechanisms, since these demyelinating central disorders. are so prominently and consistently expressed at low drug concentrations. The presence of alternative mechanisms may also help to explain the beneficial effects of 4-AP in spinal improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: assistance. The work was supported by grants from the
